Ultragenyx Pharmaceutical

Ultragenyx is a clinical-stage biotechnology company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. Founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies. Our company is led by an experienced management team in rare disease therapeutics. Recognizing that our primary responsibility is to our patients, we are working with advocacy groups to provide support and outreach to individuals and families affected by these disorders and engage them in the clinical testing process. We are also working with regulatory agencies to design and conduct high quality clinical studies that meet the requirements for approval. We are creating an improved model for successful rare disease drug development that increases efficiency and effectiveness by changing the way the process is organized and conducted. We believe that we can deliver significant value to our patients by building a diverse and high quality pipeline of rare disease therapeutics and efficiently transforming good science into great medicine. We are looking for highly motivated individuals to join our team in an exciting biotechnology environment. If you are looking for a meaningful position that has the ability to transform the lives of patients and be part of a high performance team focused on the same goal, this is the opportunity you have been waiting for.

Company Growth (employees)
Novato, US
Size (employees)
376 (est)+31%
Ultragenyx Pharmaceutical was founded in 2010 and is headquartered in Novato, US

Ultragenyx Pharmaceutical Office Locations

Ultragenyx Pharmaceutical has an office in Novato
Novato, US (HQ)
77 Digital Drive

Ultragenyx Pharmaceutical Metrics

Ultragenyx Pharmaceutical Financial Metrics

Ultragenyx Pharmaceutical's revenue was reported to be $133 k in FY, 2016

Revenue (FY, 2016)

$133 k

Net income (FY, 2016)

($245.9 m)

EBIT (FY, 2016)

($248 m)

Market capitalization (22-May-2017)

$2.4 b

Closing share price (22-May-2017)


Cash (31-Dec-2016)

$161.1 m
Ultragenyx Pharmaceutical's current market capitalization is $2.4 b.
FY, 2014FY, 2015FY, 2016


$133 k

R&D expense

$46 m$114.7 m$183.2 m

General and administrative expense

$10.8 m$33 m$64.9 m

Operating expense total

$56.8 m$147.7 m$248.1 m


($56.8 m)($147.7 m)($248 m)

EBIT margin, %


Interest income

$608 k$2.3 m$3.8 m

Pre tax profit

($245.8 m)

Income tax expense

($35 k)

Net Income

($59.8 m)($145.6 m)($245.9 m)
FY, 2014FY, 2015FY, 2016


$24.3 m$93.6 m$161.1 m


$5.9 m$13.1 m$20.1 m

Current Assets

$193.4 m$450.2 m$401.7 m


$3 m$7.4 m$17.1 m

Total Assets

$198 m$559.6 m$540.6 m

Accounts Payable

$4.9 m$2.9 m$5.4 m

Current Liabilities

$12.5 m$27.9 m$60.3 m

Additional Paid-in Capital

$324.1 m$816.6 m$1 b

Retained Earnings

($139 m)($284.7 m)($530.5 m)

Total Equity

$531.1 m$474 m

Financial Leverage

1.1 x1.1 x
FY, 2014FY, 2015FY, 2016

Net Income

($59.8 m)($145.6 m)($245.9 m)

Depreciation and Amortization

$684 k$1.4 m$3.4 m


($4.1 m)($7.1 m)($7.1 m)

Accounts Payable

$3.2 m($2 m)$2.5 m

Cash From Operating Activities

($44.6 m)($106 m)($161 m)

Purchases of PP&E

($2.1 m)($5 m)($10.2 m)

Cash From Investing Activities

($123.4 m)($292.4 m)$89.9 m

Cash From Financing Activities

$185 m$467.6 m$138.7 m
Y, 2016



Financial Leverage

1.1 x

Ultragenyx Pharmaceutical Market Value History

Ultragenyx Pharmaceutical Company Life

You may also be interested in